Alpha 2.0
Login Register
» Articles » PMID: 8112353

Antimicrobial Drug Use in Hospitals in The Netherlands, Germany and Belgium

Overview
Journal Eur J Clin Microbiol Infect Dis
Publisher Springer
Specialties Infectious Diseases
Microbiology
Date 1993 Nov 1
PMID 8112353
Citations 6
Authors
R Janknegt
W J Wijnands
M Caprasse
W BRANDENBURG
M G Schuitenmaker
E Stobberingh
Affiliations
Soon will be listed here.
Abstract

Data on the use of antimicrobial drugs was collected by means of an inquiry to 30 hospitals in Belgium (15 in Dutch sectors and 15 in the French sectors), 21 hospitals in Germany and 20 hospitals in the Netherlands. The use of these drugs was expressed as the number of defined daily doses (DDD) per 100 bed days by the anatomical therapeutical chemical classification system. The total use of antimicrobial agents was significantly (p < 0.001) higher in both parts of Belgium (55.6 and 52.0 DDD per 100 bed days) than in Germany (37.9 DDD) or the Netherlands (34.1 DDD). In particular, amoxicillin-clavulanic acid, the first- and second-generation cephalosporins, aminoglycosides and fluoroquinolones were used more in Belgium than in either of the other countries. At least part of the differences observed in antimicrobial drug use could be explained by differences in written antibiotic policy.

Citing Articles

Drug use in relation to clinical activities as an instrument for prospective drug budgeting. The Belgian experience.

Closon M, Crott R, Even-Adin D Pharmacoeconomics. 1996; 9(3):246-63.

PMID: 10160100 DOI: 10.2165/00019053-199609030-00006.

The system of objective judgement analysis method: less objectivity than pretended?.

Schacht P, Bosse D, KUBIN R Pharmacoeconomics. 1995; 7(2):180-2.

PMID: 10155304 DOI: 10.2165/00019053-199507020-00009.

Implementation of an educational program and an antibiotic order form to optimize quality of antimicrobial drug use in a department of internal medicine.

Gyssens I, Blok W, van den Broek P, Hekster Y, van der Meer J Eur J Clin Microbiol Infect Dis. 1998; 16(12):904-12.

PMID: 9495671 DOI: 10.1007/BF01700557.

The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations.

Janknegt R Pharm World Sci. 1997; 19(3):133-41.

PMID: 9259029 DOI: 10.1023/a:1008609718457.

Multiply resistant pneumococci in The Netherlands.

Holloway Y, Schiphuis J, Kooistra-Smid M, Snijder J, Appelbaum P, Spangler S Eur J Clin Microbiol Infect Dis. 1994; 13(4):322-3.

PMID: 8070440 DOI: 10.1007/BF01974612.

References
1.
Swinscow T . XI--The t tests. Br Med J. 1976; 2(6030):291-2. PMC: 1687887. DOI: 10.1136/bmj.2.6030.291. View
2.
Buirma R, Horrevorts A, Wagenvoort J . Incidence of multi-resistant gram-negative isolates in eight Dutch hospitals. The 1990 Dutch Surveillance Study. Scand J Infect Dis Suppl. 1991; 78:35-44. View
3.
Verbist L . Incidence of multi-resistance in gram-negative bacterial isolates from intensive care units in Belgium: a surveillance study. Scand J Infect Dis Suppl. 1991; 78:45-53. View
4.
Neu H, DUMA R, Jones R, McGowan Jr J, OBrien T, Sabath L . Therapeutic and epidemiologic recommendations to reduce the spread of type-I beta-lactamase resistance. Diagn Microbiol Infect Dis. 1992; 15(2 Suppl):49S-52S. View
5.
. Susceptibility to beta-lactam antibiotics in septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance. Eur J Clin Microbiol. 1987; 6(5):515-20. DOI: 10.1007/BF02014238. View